111 related articles for article (PubMed ID: 21741004)
21. Direct-acting antiviral agents against hepatitis C virus and lipid metabolism.
Kanda T; Moriyama M
World J Gastroenterol; 2017 Aug; 23(31):5645-5649. PubMed ID: 28883690
[TBL] [Abstract][Full Text] [Related]
22. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
[TBL] [Abstract][Full Text] [Related]
23. HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
Yu ML; Lee CM; Chuang WL; Lu SN; Dai CY; Huang JF; Lin ZY; Hu TH; Chen CH; Hung CH; Wang JH; Chen CL; Kao JH; Lai MY; Liu CH; Su TH; Wu SS; Liao LY; Kuo HT; Chao YC; Tung SY; Yang SS; Chen PJ; Liu CJ; Chen DS
J Infect Dis; 2010 Jul; 202(1):86-92. PubMed ID: 20482252
[TBL] [Abstract][Full Text] [Related]
24. Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.
Aziz H; Raza A; Waheed Y; Gill U; Gill ML
Int J Infect Dis; 2012 Aug; 16(8):e597-602. PubMed ID: 22658873
[TBL] [Abstract][Full Text] [Related]
25. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
Kamal SM; El Kamary SS; Shardell MD; Hashem M; Ahmed IN; Muhammadi M; Sayed K; Moustafa A; Hakem SA; Ibrahiem A; Moniem M; Mansour H; Abdelaziz M
Hepatology; 2007 Dec; 46(6):1732-40. PubMed ID: 17943989
[TBL] [Abstract][Full Text] [Related]
26. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
27. Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.
Pattullo V; Ravindran NC; Mazzulli T; Wong DK; Heathcote EJ
J Viral Hepat; 2010 Dec; 17(12):834-8. PubMed ID: 20196800
[TBL] [Abstract][Full Text] [Related]
28. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.
Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G
J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817
[TBL] [Abstract][Full Text] [Related]
29. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: propensity score-matched analysis.
Yokoyama S; Kawakami Y; Imamura M; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Takahashi S; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
J Gastroenterol Hepatol; 2015 Feb; 30(2):337-44. PubMed ID: 25091289
[TBL] [Abstract][Full Text] [Related]
30. Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Macías J; Rivero A; Cifuentes C; Camacho A; Neukam K; Rivero-Juárez A; Mira JA; Torre-Cisneros J; Gómez-Mateos J; Pineda JA
Enferm Infecc Microbiol Clin; 2013; 31(7):424-9. PubMed ID: 23453582
[TBL] [Abstract][Full Text] [Related]
31. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus.
Yu JW; Sun LJ; Zhao YH; Kang P; Gao J; Li SC
Liver Int; 2009 Nov; 29(10):1485-93. PubMed ID: 19602134
[TBL] [Abstract][Full Text] [Related]
33. Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders.
Nagaki M; Shimizu M; Sugihara JI; Tomita E; Sano C; Naiki T; Kimura K; Amano K; Sakai T; Ninomiya M; Kojima T; Katsumura N; Fujimoto M; Moriwaki H
Aliment Pharmacol Ther; 2009 Aug; 30(4):343-51. PubMed ID: 19485982
[TBL] [Abstract][Full Text] [Related]
34. Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection.
Pedersen C; Alsiö Å; Lagging M; Langeland N; Färkkilä M; Buhl MR; Mørch K; Westin J; Sangfelt P; Norkrans G; Christensen PB;
J Viral Hepat; 2011 Apr; 18(4):245-51. PubMed ID: 20384961
[TBL] [Abstract][Full Text] [Related]
35. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner.
Clark PJ; Thompson AJ; Vock DM; Kratz LE; Tolun AA; Muir AJ; McHutchison JG; Subramanian M; Millington DM; Kelley RI; Patel K
Hepatology; 2012 Jul; 56(1):49-56. PubMed ID: 22318926
[TBL] [Abstract][Full Text] [Related]
37. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
[TBL] [Abstract][Full Text] [Related]
38. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
[TBL] [Abstract][Full Text] [Related]
39. [The effect of patient's body weight, gender and baseline viral load on the efficacy of hepatitis C therapy].
Husa P; Slesinger P; Stroblová H; Svobodník A
Vnitr Lek; 2006 Jun; 52(6):590-5. PubMed ID: 16871762
[TBL] [Abstract][Full Text] [Related]
40. Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.
Belhadj N; Houissa F; Elloumi H; Ouakaa A; Gargouri D; Romani M; Kilani A; Kochlef A; Kharrat J; Ghorbel A
Tunis Med; 2008 Apr; 86(4):341-5. PubMed ID: 19476135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]